Breaking News Instant updates and real-time market news.

NFLX

Netflix

$99.80

-1.67 (-1.65%)

, UNH

UnitedHealth

$142.01

7.875 (5.87%)

09:55
10/18/16
10/18
09:55
10/18/16
09:55

Early notable gainers among liquid option names on October 18th

Notable gainers among liquid option names this morning include Netflix (NFLX) $118.71 +18.96, UnitedHealthcare (UNH) $141.27 +7.23, Harley Davidson (HOG) $52.35 +2.66, Endo (ENDP) $19.78 +0.52, and NRG Energy (NRG) $11.25 +0.28.

NFLX

Netflix

$99.80

-1.67 (-1.65%)

UNH

UnitedHealth

$142.01

7.875 (5.87%)

HOG

Harley-Davidson

$51.40

1.7 (3.42%)

ENDP

Endo

$19.27

-0.59 (-2.97%)

NRG

NRG Energy

$11.24

0.27 (2.46%)

  • 18

    Oct

  • 18

    Oct

  • 04

    Nov

  • 08

    Nov

  • 29

    Nov

NFLX Netflix
$99.80

-1.67 (-1.65%)

10/18/16
NEED
10/18/16
NO CHANGE
NEED
Hold
Needham sees Netflix programming pivot as 'key story' of the quarter
Needham analyst Laura Martin notes that Netflix beat revenue, subscriber guidance and estimates in Q3, and sees its programming pivot as the key story of the quarter. Although the pivot toward more owned programming hurts margins and free cash flow in the near term, the analyst likes the fact that Netflix is now building a content library. Martin reiterates a Hold rating on the shares.
10/18/16
COWN
10/18/16
NO CHANGE
Target $150
COWN
Outperform
Netflix price target raised to $150 from $110 at Cowen
Cowen analyst John Blackledge raised his price target on Netflix to $150 from $110. The analyst cited the better than expected subscriber additions and better than expected guidance. Blackledge reiterated his Outperform rating on Netflix shares.
10/18/16
RBCM
10/18/16
NO CHANGE
RBCM
Netflix price target raised to $150 from $130 at RBC Capital
RBC Capital analyst Mark Mahaney raised his price target on Netflix after all of the company's guidance metrics beat expectations. The analyst thinks that the company's fundamentals are continuing to improve, and he keeps an Outperform rating on the shares.
10/18/16
ADAM
10/18/16
NO CHANGE
Target $140
ADAM
Buy
Netflix price target raised to $140 from $115 at Canaccord
Canaccord analyst Michael Graham raised his price target on Netflix to $140 from $115 following strong Q3 results. The analyst noted the subscriber growth was ahead of guidance and ahead of his own expectations. Graham also pointed to the company's plans to ramp original content more quickly and said it is still early on penetrating international markets. Graham reiterated his Buy rating on Netflix shares.
UNH UnitedHealth
$142.01

7.875 (5.87%)

09/22/16
EVER
09/22/16
INITIATION
Target $155
EVER
Buy
UnitedHealth initiated with a Buy at Evercore ISI
Evercore ISI initiated UnitedHealth with a Buy and a $155 price target.
09/22/16
PIPR
09/22/16
NO CHANGE
Target $155
PIPR
Overweight
UnitedHealth won VA contract worth $1B per year, says Piper Jaffray
Piper Jaffray analyst Sean Wieland says UnitedHealth unit Optum has won a contract with the U.S. Department of Veterans Affairs to provide medical disability examinations. The analyst estimates the contract, awarded to Optum wholly owned subsidiaries Logistics Health and Medical Support Los Angeles, represents $1B per year. Wieland estimates the award will be neutral to earnings in year one and become accretive in 2018. He reiterates an Overweight rating on UnitedHealth shares with a $155 price target.
09/14/16
ADAM
09/14/16
NO CHANGE
Target $155
ADAM
Buy
LabCorp weakness a buying opportunity, says Canaccord
Canaccord analyst Mark Massaro noted LabCorp (LH) shares sold off yesterday on news that its rival, Quest Diagnostics (DGX), announced a partnership with Optum, a subsidiary of UnitedHealth (UNH). The analyst said LabCorp does not believe Quest can wrestle away UnitedHealth's long-standing lab services contract when it goes up for renewal in 2018. Massaro expects LabCorp to deliver steady quarterly beats and said the company is well positioned to capture its losses in the second half of 2016. Massaro reiterated his Buy rating and $155 price target on LabCorp shares.
09/13/16
CHLM
09/13/16
NO CHANGE
CHLM
LabCorp impact from Quest-Optum collaboration limited, says Craig-Hallum
Craig-Hallum analyst Bill Bonello said the Quest Diagnostics (DGX) and Optum, a division of United Healthcare (UNH), collaboration does not put LabCorp's (LH) revenue at risk. The collaboration does not create any lab benefit management service, or a preferred lab network with Quest at the hub, that would drive business to Quest labs or compete with Labcorp's Beacon LBS lab management business, the analyst wrote. Bonellow said UnitedHealthcare and LabCorp continue to work together to expand the Beacon LBS model to other markets and we would expect to see the Beacon lab network expand to other payors overtime. Also, the analyst said the collaboration does not impact LabCorp's contract with UnitedHealthcare, or UHC, and and has no impact on that contract today and does not imply a change to UHC's contracting strategy going forward. Bonello rates LabCorp a Buy with a $160 price target.
HOG Harley-Davidson
$51.40

1.7 (3.42%)

09/30/16
JEFF
09/30/16
INITIATION
Target $49
JEFF
Hold
Harley-Davidson initiated with a Hold at Jefferies
Jefferies analyst Trevor Young started Harley-Davidson (HOG) with a Hold rating and $49 price target. The analyst is concerned about peaking U.S. motorcycle demand and Harley's rising mix of financing. Young this morning named Fox Factory (FOXF) his top pick in Powersports.
09/16/16
WEDB
09/16/16
NO CHANGE
Target $48
WEDB
Neutral
Harley-Davidson used bike pricing getting worse, says Wedbush
Wedbush analyst James Hardiman said the firm's Harley-Davidson used bike pricing study found that used model-year 2015 bikes are selling, on average, at the largest discount seen since 2006 and that nearly all model years are seeing trade-in prices relative to their initial MSRPs that are at or near the recessionary levels of 2008-2009. The survey results are a negative both for Harley-Davidson Financial Services and for new bike demand, said Hardiman, who keeps a Neutral rating on Harley shares.
09/15/16
UBSW
09/15/16
NO CHANGE
Target $54
UBSW
Neutral
UBS sees downside risk to Harley-Davidson guidance
UBS analyst Robin Farley analyzed 25 years of inventory data for Harley-Davidson and concluded there are downside risks to the company's guidance. The analyst said the math suggests retail sales would have to grow at a mid-single digit rate and the company's second half expectations for shipments seem high. Farley maintained her Neutral rating and lowered her price target to $54 from $55 on Harley-Davidson shares.
09/30/16
09/30/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Amazon.com (AMZN) initiated with a Buy at Guggenheim. 2. Wal-Mart (WMT) initiated with an Overweight at KeyBanc and a Buy at Guggenheim. 3. Harley-Davidson (HOG) initiated with a Hold at Jefferies. 4. Coach (COH) was initiated with a Buy at Guggenheim while the firm initiated Michael Kors (KORS) with a Neutral. 5. First Solar (FSLR) initiated with a Buy at Williams Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
ENDP Endo
$19.27

-0.59 (-2.97%)

09/29/16
09/29/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. eBay (EBAY) upgraded to Buy from Hold at Deutsche Bank with analyst Ross Sandler saying eBay is likely to outperform Internet peers over the next two years now that its re-platforming is in the latter stages. 2. BlackBerry (BBRY) upgraded to Neutral from Underperform at Macquarie with analyst Gus Papageorgiou saying he expects operations to stabilize and profitability to return next year. 3. Endo (ENDP) upgraded to Outperform from Market Perform at Northland. 4. Rex Energy (REXX) upgraded to Hold from Sell at Stifel with analyst Michael Scialla saying the production cut may not actually occur, but he believes that other factors, along with positive commentary from OPEC, "appears to be building an oil price floor of $40." 5. Incyte (INCY) upgraded to Outperform from Market Perform at Raymond James with analyst Reni Benjamin saying Epacadostat plus pembrolizumab, should ;the results be confirmed in the ongoing Phase III study, could effectively compete with ipilimumab and nivolumab. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/26/16
OPCO
09/26/16
NO CHANGE
OPCO
Perform
CEO change signals new direction for Endo, says Oppenheimer
Oppenheimer analyst Marcus Ho was not entirely surprised by the appointment of Paul Campanelli to President and CEO of Endo, noting that the company has been hit hard by the recent negative commentary surrounding opioids and the erosion in the generics pricing environment. The analyst points out that management reaffirmed Q3 and full-year 2016 guidance and is now directionally focused more on operational execution, with an emphasis on pipeline and paragraph IV opportunities on the generics side and product development on the branded side. He reiterates a Perform rating on the shares.
10/14/16
GUGG
10/14/16
NO CHANGE
Target $35
GUGG
Buy
Endo could be worth $30-$51 per share, says Guggenheim
Guggenheim analyst Louise Chen said her sum-of-the-parts analysis suggests that Endo could be worth $30-$51 per share, adding that she believes the company could drive its stock price up by 50% or more if it were to sell its brand business and non-core international assets and focus on generics. If it were to opt for that route, Endo "may do better as a private company," given the lack of visibility into Par's generic pipeline and Wall Street's focus on drug pricing, added Chen. The firm has a Buy rating and $35 price target on Endo shares, which are up 1.8% to $20.16 near midday.
09/29/16
NORL
09/29/16
UPGRADE
NORL
Outperform
Endo upgraded to Outperform from Market Perform at Northland
NRG NRG Energy
$11.24

0.27 (2.46%)

01/29/16
01/29/16
INITIATION

On The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: American Equity (AEL) initiated with an Outperform at RBC Capital... Calpine (CPN) initiated with a Buy at Guggenheim... Diamondback Energy (FANG) initiated with an Outperform at BMO Capital... Dynegy (DYN) initiated with a Neutral at Guggenheim... ICF International (ICFI) initiated with a Market Perform at Barrington... Juno Therapeutics (JUNO) initiated with a Buy at SunTrust... Kite Pharma (KITE) initiated with a Buy at SunTrust... Match Group (MTCH) initiated with a Neutral at Susquehanna... Medifast (MED) initiated with a Hold at Wunderlich... NRG Energy (NRG) initiated with a Buy at Guggenheim... NRG Yield (NYLD) initiated with a Neutral at Guggenheim... Nutrisystem (NTRI) initiated with a Buy at Wunderlich... Parsley Energy (PE) initiated with an Outperform at BMO Capital... Precision Drilling (PDS) initiated with a Hold at Canaccord... RSP Permian (RSPP) initiated with an Outperform at BMO Capital... Taylor Morrison (TMHC) initiated with a Neutral at Citi... Tortoise North American Energy (TYN) initiated with a Neutral at Guggenheim... WisdomTree (WETF) initiated with a Neutral at Northcoast.
05/25/16
MSCO
05/25/16
NO CHANGE
MSCO
Morgan Stanley says to buy Dynegy, NRG Energy on any weakness
Morgan Stanley analyst led by Stephen Byrd said results for PJM's 2019/20 Base Residual Auction came in below expectations driven by high levels of new builds. The analyst said the outcome does not materially impact his long-term auction price or the cash flow forecasts for Dynegy DYN) and NRG Energy (NRG), and would be buyers on any weakness.
06/09/16
UBSW
06/09/16
DOWNGRADE
Target $16
UBSW
Sell
NRG Energy downgraded to Sell from Buy at UBS
UBS analyst Julien Dumoulin-Smith double downgraded NRG Energy to Sell from Buy saying the stock's risk/reward "skews negatively" following the near doubling off the January lows. The market is overlooking the $285M decrease in PJM capacity revenue, Dumoulin-Smith tells investors in a research note. He has a $16 price target for the shares.
07/26/16
DBAB
07/26/16
UPGRADE
Target $20
DBAB
Buy
Calpine upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank analyst Abe Azar upgraded Calpine (CPN) to Buy citing valuation following the year-to-date underperformance relative to peers Dynegy (DYN) and NRG Energy (NRG). The analyst views the current valuation as "reasonable" and calls Calpine lower risk. He raised his price target for the shares to $20 from $18.

TODAY'S FREE FLY STORIES

HZNP

Horizon Pharma

$19.39

-0.82 (-4.06%)

06:57
12/08/16
12/08
06:57
12/08/16
06:57
Hot Stocks
Breaking Hot Stocks news story on Horizon Pharma »

Horizon Pharma trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 14

    Dec

BLK

BlackRock

$377.52

5.84 (1.57%)

06:56
12/08/16
12/08
06:56
12/08/16
06:56
Periodicals
BlackRock signs preliminary deal to move to Manhattan's West Side, WSJ says »

BlackRock has signed a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMD

AMD

$9.56

0.11 (1.16%)

06:56
12/08/16
12/08
06:56
12/08/16
06:56
Upgrade
AMD rating change  »

AMD upgraded to Buy from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EVHC

Envision Healthcare

$69.19

-2.51 (-3.50%)

06:55
12/08/16
12/08
06:55
12/08/16
06:55
Initiation
Envision Healthcare initiated  »

Envision Healthcare…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

06:55
12/08/16
12/08
06:55
12/08/16
06:55
General news
NYMEX crude is showing a 0.8% gain »

NYMEX crude is showing a…

MEI

Methode Electronics

$39.00

0.45 (1.17%)

06:54
12/08/16
12/08
06:54
12/08/16
06:54
Earnings
Methode Electronics raises FY17 EPS view to $2.30-$2.45 from $2.11-$2.35 »

Consensus for FY17 EPS is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

IGT

International Game

$25.49

0.36 (1.43%)

, SNE

Sony

$28.61

0.45 (1.60%)

06:54
12/08/16
12/08
06:54
12/08/16
06:54
Hot Stocks
International Game signs license agreement with Sony Pictures Television »

International Game…

IGT

International Game

$25.49

0.36 (1.43%)

SNE

Sony

$28.61

0.45 (1.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MEI

Methode Electronics

$39.00

0.45 (1.17%)

06:53
12/08/16
12/08
06:53
12/08/16
06:53
Earnings
Methode Electronics reports Q2 EPS 66c, consensus 55c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

VRNT

Verint

$38.30

0.1 (0.26%)

06:52
12/08/16
12/08
06:52
12/08/16
06:52
Recommendations
Verint analyst commentary  »

Verint removed from Focus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

AMC

AMC Entertainment

$32.65

-1.15 (-3.40%)

, CKEC

Carmike Cinemas

$33.45

-0.4 (-1.18%)

06:49
12/08/16
12/08
06:49
12/08/16
06:49
Hot Stocks
AMC Entertainment and Carmike Cinemas announce election deadline »

AMC Theatres (AMC) and…

AMC

AMC Entertainment

$32.65

-1.15 (-3.40%)

CKEC

Carmike Cinemas

$33.45

-0.4 (-1.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCBFF

Standard Chartered

$8.68

0.28 (3.33%)

06:47
12/08/16
12/08
06:47
12/08/16
06:47
Periodicals
StanChart sanctions investigation nearing completion, Bloomberg reports »

U.S. investigators have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HP

Helmerich & Payne

$80.86

0.94 (1.18%)

06:46
12/08/16
12/08
06:46
12/08/16
06:46
Downgrade
Helmerich & Payne rating change  »

Helmerich & Payne…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LULU

lululemon

$59.84

2.6 (4.54%)

06:45
12/08/16
12/08
06:45
12/08/16
06:45
Upgrade
lululemon rating change  »

lululemon upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jan

PRGO

Perrigo

$83.94

-0.53 (-0.63%)

06:44
12/08/16
12/08
06:44
12/08/16
06:44
Hot Stocks
Perrigo announces portfolio review developments, intends to restructure BCH unit »

Perrigo announced its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CEB

CEB

$59.50

0.35 (0.59%)

06:43
12/08/16
12/08
06:43
12/08/16
06:43
Downgrade
CEB rating change  »

CEB downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UHS

Universal Health

$111.36

-15.01 (-11.88%)

06:42
12/08/16
12/08
06:42
12/08/16
06:42
Hot Stocks
Universal Health issues statement on recent BuzzFeed article »

Universal Health issued a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

GOOGL

Alphabet Class A

$791.47

15.29 (1.97%)

, GOOG

Alphabet

$771.19

12.08 (1.59%)

06:42
12/08/16
12/08
06:42
12/08/16
06:42
Recommendations
Alphabet Class A, Alphabet, Facebook, Amazon.com analyst commentary  »

Citi replaces Amazon with…

GOOGL

Alphabet Class A

$791.47

15.29 (1.97%)

GOOG

Alphabet

$771.19

12.08 (1.59%)

FB

Facebook

$117.95

0.64 (0.55%)

AMZN

Amazon.com

$770.42

5.7 (0.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Jan

SMG

Scotts Miracle-Gro

$92.84

2.01 (2.21%)

06:41
12/08/16
12/08
06:41
12/08/16
06:41
Upgrade
Scotts Miracle-Gro rating change  »

Scotts Miracle-Gro…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARAY

Accuray

06:40
12/08/16
12/08
06:40
12/08/16
06:40
Hot Stocks
Accuray reports first patients treated with new Radixact system »

Accuray announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

TAX

Liberty Tax

$13.35

0.5 (3.89%)

06:38
12/08/16
12/08
06:38
12/08/16
06:38
Earnings
Liberty Tax reports Q2 EPS (72c), consensus (71c) »

Reports Q2 revenue $7.2M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

ZEN

Zendesk

$21.15

-0.02 (-0.09%)

06:38
12/08/16
12/08
06:38
12/08/16
06:38
Conference/Events
Zendesk management to meet with William Blair »

Group luncheon with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

AMZN

Amazon.com

$770.42

5.7 (0.75%)

06:38
12/08/16
12/08
06:38
12/08/16
06:38
Periodicals
Amazon seeks to help publishers profit more from ads, WSJ says »

Amazon is advancing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INFN

Infinera

$8.48

0.01 (0.12%)

06:37
12/08/16
12/08
06:37
12/08/16
06:37
Conference/Events
Infinera management to meet with William Blair »

Group luncheon with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

LLL

L-3 Communications

$161.56

3.1 (1.96%)

06:36
12/08/16
12/08
06:36
12/08/16
06:36
Downgrade
L-3 Communications rating change  »

L-3 Communications…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLL

Ball Corp.

$75.58

1.38 (1.86%)

06:34
12/08/16
12/08
06:34
12/08/16
06:34
Recommendations
Ball Corp. analyst commentary  »

Ball Corp. recent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.